If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Emgality Summary of Product Characteristics (SmPC)
How should a missed or incomplete loading dose of Emgality® ▼ (galcanezumab) be managed?
In the event of a missed or incomplete loading dose of galcanezumab, complete the loading dose as soon as possible. Then continue with the monthly maintenance dose from the date of last dose.
of Missed or Incomplete Galcanezumab Loading Dose
recommended dose is 120 mg galcanezumab injected subcutaneously once
monthly, with a 240 mg loading dose as the initial dose.1
should be instructed to inject a missed dose as soon as possible and
then resume monthly dosing.1
healthy subjects and patients with episodic or chronic migraine,
galcanezumab has a
modeling of phase 3 data confirmed that
240 mg loading dose achieved steady-state galcanezumab
concentrations by month 1 for the 120 mg monthly dose regimen, and
a loading dose, the 120 mg monthly dose did not achieve steady state
until 4 to 5 months.3
Emgality [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Kielbasa W, Helton DL. A new era for migraine: Pharmacokinetic and
pharmacodynamic insights into monoclonal antibodies with a focus on
galcanezumab, an anti-CGRP antibody. Cephalalgia.
Kielbasa W,Quinlan T. Population pharmacokinetics of galcanezumab,
an anti-CGRP antibody, following subcutaneous dosing to healthy
individuals and patients with migraine. J Clin Pharmacol.
= elimination half-life
= time of maximum observed drug concentration
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:June 05, 2020
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org